During the past decade, Nemocnice Novy Jicin a.s. conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 10 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nemocnice Novy Jicin a.s." #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "VectivBio AG" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored and "Ferring Pharmaceuticals" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nemocnice Novy Jicin a.s." #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Fresenius Medical Care North America" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Nemocnice Novy Jicin a.s." are "Psoriasis" (6 trials), "Atopic Dermatitis" (3 trials), "Short Bowel Syndrome" (2 trials), "Asthma" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Nemocnice Novy Jicin a.s." in a lesser frequency.

Most popular intervention types in "Nemocnice Novy Jicin a.s." are "Drug" (18 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Baricitinib" (3 trials), "BMS-986165" (2 trials), "Apraglutide" (1 trials) and "Apremilast" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nemocnice Novy Jicin a.s." are 18 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Nemocnice Novy Jicin a.s.". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Nemocnice Novy Jicin a.s., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Nemocnice Novy Jicin a.s., 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Nemocnice Novy Jicin a.s. has several departments that took part in Clinical trials: "Nemocnice AGEL Novy Jicin a.s.; Oddeleni radioterapie a onkologie" - 3 trials